Journal of Interventional Cardiac Electrophysiology

, Volume 17, Issue 3, pp 225–236

Socio-economic analysis of cardiac resynchronization therapy

Article
  • 73 Downloads

Abstract

The field of electrical device therapy has benefited from two basically independent lines of investigation demonstrating mortal benefit from either cardiac resynchronization therapy (CRT) or implantable cardioverter-defibillator (ICD) therapy in patients with heart failure. Current clinical evidence data is insufficient to conclude that CRT-defibrillation (CRTD) offers an advantage over CRT-pacing (CRTP) alone. The cost of adding a defibrillator to the CRTP device is substantial and will act as a barrier to wide scale penetration. Annualized sudden death rates are very low in certain primary prevention populations. Consequently, the potential for overtreatment is very large and the negative costs of ICD therapy are distributed equally among those patients who will have a life saving benefit and those who were “destined" never to require the therapy. The perception that these costs are acceptable if lives are saved is commonly cited as justification for expensive therapy on a population scale, but there is an important and practical difference between costs per unit life saved and costs among patients who really never needed the device. Until the a priori predictors of volumetric response to CRT are better understood, the use of CRTD in class IV patients should be discouraged since ICD therapy is unlikely to extend life in volumetric non-responders. Similarly, the use of CRTD in patients who are “destined" for significant volumetric response is probably unwise since their risk of sudden death is minimized due to favorable substrate modification. Clinical trials comparing conventional ICDs, CRTP and CRTD are necessary to rationalize use of expensive hardware resources among different patient populations. Additionally, the importance of patient preference regarding end of life care should receive greater emphasis. While CRTP may be considered palliative in terminal heart failure, the decision to offer CRTD must include a discussion with the patient regarding mode of death and the potential for the defibrillator to replace a sudden and peaceful death with a prolonged death from progressive pump failure.

Keywords

Heart failure Cardiac arrest Mortality 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schocken, D. D., Arrieta, M. I., leaverton, P. E., & Ross, E.A. (1992). Prevalence and mortality of congestive heart failure in the United States. Journal of the American College of Cardiology, 20, 301–306.PubMedCrossRefGoogle Scholar
  2. 2.
    Ho, K. K. L., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993) Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation, 88, 107–115.PubMedGoogle Scholar
  3. 3.
    Massie, B. M., & Shah, N. B. (1997). Evolving trends in the epidemiologic factors of heart failure. American Heart Journal, 133, 703–712.PubMedCrossRefGoogle Scholar
  4. 4.
    Kannel, W. B., Plehn, J. F., & Cupples, A. (1988). Cardiac failure and sudden death in the Framingham Study. American Heart Journal, 115, 869–875.PubMedCrossRefGoogle Scholar
  5. 5.
    SOLVD Investigators (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine, 327, 685–691.CrossRefGoogle Scholar
  6. 6.
    Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Hartson, W. E., Tristani, F. E., et al. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a veterans administration cooperative study. New England Journal of Medicine, 314, 1547–1552.PubMedCrossRefGoogle Scholar
  7. 7.
    Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., et al. (1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New England Journal of Medicine, 325, 303–310.PubMedCrossRefGoogle Scholar
  8. 8.
    Singh, S. N., Fletcher, R. D., Fisher, S. G., Singh, B. N., Lewis, H. D., Deedwania, P. C., et al. (1995). Amiodarone among patients with congestive heart failure and asymptomatic ventricular arrhythmias. New England Journal of Medicine, 333, 77–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Teerlink, J. R., Jalaluddin, M., Anderson, S., Kukin, M. L., Eichhorn, E. J., Francis, G., et al. (2000). Ambulatory ventricular arrhythmias among patients with heart failure do not specifically predict an increased risk of sudden death. Circulation, 101, 40–46.PubMedGoogle Scholar
  10. 10.
    American Heart Association (2003). Heart disease and stroke statistics-2003 update.Google Scholar
  11. 11.
    MERIT-HF Study Group (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet, 353, 2001–2007.CrossRefGoogle Scholar
  12. 12.
    Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality among patients with chronic heart failure. New England Journal of Medicine, 334, 1349–1355.PubMedCrossRefGoogle Scholar
  13. 13.
    CIBIS II Investigators (1999). The cardiac insufficiency bisoprolol study II: A randomized trial. Lancet, 353, 9–13.CrossRefGoogle Scholar
  14. 14.
    Moss, A. J. (1993). Sudden cardiac death and national health. Pacing and Clinical Electrophysiology, 16, 2190–2191.PubMedCrossRefGoogle Scholar
  15. 15.
    The Antiarrhythmics versus Implantable Defibrillator (AVID) Investigators (1997). A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New England Journal of Medicine, 337, 1576–1583.CrossRefGoogle Scholar
  16. 16.
    Kuck, K. H., Cappato, R., Siebels, J., Ruppel, F., for the CASH Investigators (2000). Randomized comparison of antiarrhythmia drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation, 102, 748–754.PubMedGoogle Scholar
  17. 17.
    Connolly, S. J., Gent, M., Roberts, R. S., Dorian, P., Roy, D., Sheldon, R. S., et al. (2000). Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation, 101, 1297–1302.PubMedGoogle Scholar
  18. 18.
    Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., et al. (1996). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. New England Journal of Medicine, 335, 1933–1940.PubMedCrossRefGoogle Scholar
  19. 19.
    Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., Hafley, G. et al. (1999). A randomized study of the prevention of sudden death among patients with coronary artery disease. New England Journal of Medicine, 341, 1882–1890.PubMedCrossRefGoogle Scholar
  20. 20.
    Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., et al. (2002). Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine, 346, 877–883.PubMedCrossRefGoogle Scholar
  21. 21.
    Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., et al. (2005). Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine, 352, 225–237.PubMedCrossRefGoogle Scholar
  22. 22.
    Vassalo, J. A., Cassidy, D. M., Miller, J. M., Buxton, A. E., Marchlinski, F. E., et aL. (1986). Left ventricular endocardial activation during right ventricular pacing: Effect of underlying heart disease. Journal of the American College of Cardiology, 7, 1228–1233.CrossRefGoogle Scholar
  23. 23.
    Prinzen, F. W., & Peschar, M. (2002). Relation between the pacing induced sequence of activation and left ventricular pump function in animals. Pacing and Clinical Electrophysiology, 25, 484–498.PubMedCrossRefGoogle Scholar
  24. 24.
    Prinzen, F. W., Augustijn, C. H., Arts, T., Allessi, M. A., & Reneman, R. S. (1990). Redistribution of myocardial fiber strain and blood flow by asynchronous activation. American Journal of Physiology, H300–H308.Google Scholar
  25. 25.
    Thambo, J.-.B, Bordachar, P., Garrigue, S., Lafitte, S., Sanders, P., Reuter, S., et al. (2004). Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation, 110, 3766–3772.PubMedCrossRefGoogle Scholar
  26. 26.
    Kanzaki, H., Bazaz, R., Schwartzman, D., Dohi, K., Sade, L. E., Gorscan, J. 3rd (2004). A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: Insights from mechanical activation strain mapping. Journal of the American College of Cardiology, 44, 1619–1625.PubMedCrossRefGoogle Scholar
  27. 27.
    Maurer, G., Torres, M. A. R., Corday, E., Haendchen, R. V., & Meerbaum, S. (1984). Two-dimensional echocardiographic contrast assessment of pacing-induced mitral regurgitation: Relation to altered regional left ventricular function. Journal of the American College of Cardiology, 3, 986–991.PubMedCrossRefGoogle Scholar
  28. 28.
    Vanderheyden, M., Goethals, M., Anguera, I., Nellens, P., Andries, E., Brugada, J., et al. (1997). Hemodynamic deterioration following radiofrequency ablation of the atrioventricular conduction system. Pacing and Clinical Electrophysiology, 20, 2422–2428.PubMedCrossRefGoogle Scholar
  29. 29.
    Nielsen, J. C., Kristensen, L., Andersen, H. R., Mortensen, P. T., Pedersen, O., Pedersen, A. K. (2003). A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: Echocardiographic and clinical outcome. Journal of the American College of Cardiology, 42, 614–623.PubMedCrossRefGoogle Scholar
  30. 30.
    Nielsen, J. C., Andersen, H. R., Thomsen, P. E. B., Thuesen, L., Mortensen, P. T., Vesterlund, T., et al. (1998). Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation, 97, 987–995.PubMedGoogle Scholar
  31. 31.
    Nahlawi, M., Waligora, M., Spies, S. M., Bonow, R. O., Kadish, A. H., & Goldberger, J. (2004). Left ventricular function during and after right ventricular pacing. Journal of the American College of Cardiology, 44, 1883–1888.PubMedCrossRefGoogle Scholar
  32. 32.
    Sweeney, M. O., Hellkamp, A. S., Ellenbogen, K. A., Greenspon, A. J., Freedman, R. A., Lee, K. L., et al. (2003). Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation, 23, 2932–2937.CrossRefGoogle Scholar
  33. 33.
    Steinberg, J. S., Fischer, A., Wang, P., Schuger, C., Daubert, J., McNitt, S., et al. (2005). The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II. Journal of Cardiovascular Electrophysiology, 16, 359–365.PubMedCrossRefGoogle Scholar
  34. 34.
    The DAVID Trial Investigators (2002). Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA, 288, 3115–3123.CrossRefGoogle Scholar
  35. 35.
    Shamim, W., Francis, D. P., Yousufuddin, M., Varney, S., Pieopli, M. F., Anker, S. D., et al. (1999). Intra-ventricular conduction delay: A prognostic marker in congestive heart failure. International Journal of Cardiology, 70, 171–178.PubMedCrossRefGoogle Scholar
  36. 36.
    Gerber, T. C., Nishimura, R., Holmes, D. R., Lloyd, M. A., Zehr, K. J., Tajik, A. Z., et al. (2001). Left ventricular and biventricular pacing in congestive heart failure. Mayo Clinic Proceedings, 706, 803–812.CrossRefGoogle Scholar
  37. 37.
    Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., et al. (2002). Cardiac resynchronization in chronic heart failure. New England Journal of Medicine, 346, 1845–1853.PubMedCrossRefGoogle Scholar
  38. 38.
    Cazeau, S., Leclerlq, C., Lavergne, T., Walker, S., Varma, C., Linde, C., et al. (2001). Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. New England Journal of Medicine, 344, 873–880.PubMedCrossRefGoogle Scholar
  39. 39.
    Auricchio, A., Stellbrink, C., Sack, S., Block, M., Vogt, J., Bakker, P., et al. (2002). Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Journal of the American College of Cardiology, 39, 2026–2033.PubMedCrossRefGoogle Scholar
  40. 40.
    Cleland, J. G. F., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. New England Journal of Medicine, 352, 1539–1549.PubMedCrossRefGoogle Scholar
  41. 41.
    Bradley, D. J., Bradley, E. A., Baughman, K. L., Berger, R. D., Calkins, H., & Goodman, S. N. (2003). Cardiac resynchronization and death from progressive heart failure: A meta-analysis of randomized controlled trials. JAMA, 289, 730–740.PubMedCrossRefGoogle Scholar
  42. 42.
    Higgins, S. L., Hummel, J. D., Niazi, I. K., Giudici, M. C., Worley, S. J., Saxon, L. A., et al. (2003). Cardiac resynchronization therapy for the treatment of heart failure and intraventricular conduction delay and malignant ventricular tachyarrhythmia. Journal of the American College of Cardiology, 42, 1454–1459.PubMedCrossRefGoogle Scholar
  43. 43.
    Young, J. B., Abraham, W. T., Smith, A. L., Leon, A. R., Lieberman, R., Wilkoff, B., et al. (2003). Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA, 289, 2685–2694.PubMedCrossRefGoogle Scholar
  44. 44.
    Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 350, 2140–2150.PubMedCrossRefGoogle Scholar
  45. 45.
    Daubert, J. C., Leclercq, C., & Mabo, P. (2005). There is plenty of room for cardiac resynchronization therapy devices without back-up defibrillators in the electrical treatment of heart failure. Journal of the American College of Cardiology, 46, 2204–2207.PubMedCrossRefGoogle Scholar
  46. 46.
    Ellenbogen, K. A., Wood, M. A., & Klein, H. U. (2005). Why should we care about CARE-HF? Journal of the American College of Cardiology, 46, 2199–2203.PubMedCrossRefGoogle Scholar
  47. 47.
    Hlatky, M. A. (2005) Cost effectiveness of cardiac resynchronization therapy. Journal of the American College of Cardiology, 46, 2322–2324.PubMedCrossRefGoogle Scholar
  48. 48.
    Pratt, C. M., Greenway, P. A., Schoenfeld, M. L., Hibben, M. L., & Reiffel, J. A. (1996). Exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials. Circulation, 93, 519–524.PubMedGoogle Scholar
  49. 49.
    Ypenburg, C., van Erven, L., Bleeker, G. B., Bax, J. J., Bootsma, M., Wijffels, M. C., et al. (2006). Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. Journal of the American College of Cardiology, 48, 464–470.PubMedCrossRefGoogle Scholar
  50. 50.
    Ellenbogen, K. A., Levine, J. H., Berger, R. D., Daubert, J. P., Winters, S. L., Greenstein, E., et al. (2006). Are implantable cardioverter-defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation, 113, 776–782.PubMedCrossRefGoogle Scholar
  51. 51.
    Wathen, M. S., DeGroot, P. J., Sweeney, M. O., Stark, A. J., Otterness, M. F., Adkisson, W. O., et al. (2004). Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators. PainFREE Rx II Trial Results. Circulation, 110, 2592–2596.CrossRefGoogle Scholar
  52. 52.
    Shukla, G., Chaudry, M., Orlov, M., Hoffmeister, P., & Haffajee, C. (2005). Potential proarrhythmic effect of biventricular pacing: Fact or myth? Heart Rhythm, 2, 951–956.PubMedCrossRefGoogle Scholar
  53. 53.
    Guerra, J., Wu, J., Miller, J. M., & Groh, W. J. (2003). Increase in ventricular tachycardia frequency after biventricular implantable cardioverter defibrillator upgrade. Journal of Cardiovascular Electrophysiology, 14, 1245-124.CrossRefGoogle Scholar
  54. 54.
    Fish, J. M., Di Diego, J. M., Nesterenko, V., & Antzelevitch, C. (2004). Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: Implications for biventricular pacing. Circulation, 109, 2136–2142.PubMedCrossRefGoogle Scholar
  55. 55.
    Medina-Ravell, V. A., Lankipalli, R. S., Yan, G. X., Anzelevitch, C., Medina-Malpica, N. A., Droogan, C., et al. (2003). Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization. Circulation, 107, 740–746.PubMedCrossRefGoogle Scholar
  56. 56.
    Wilkoff, B., Hess, M., Young, J. D., & Abraham, W. T. (2004). Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. Journal of Cardiovascular Electrophysiology, 15, 1002–1009.PubMedCrossRefGoogle Scholar
  57. 57.
    Bansch, D., Antz, M., Boczor, S., Volkmer, M., Tebbenjohanns, J., Seidl, K., et al. (2002). Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation, 105, 1453–1458.PubMedCrossRefGoogle Scholar
  58. 58.
    Strickberger, S. A., Hummel, J. D., Bartlett, T. G., Frumin, H. I., Schuger, C. D., Beau, S. L., et al. (2003). Amiodarone vs. implantable defibrillator: Randomized trial in patients with nonischemic cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. Journal of the American College of Cardiology, 41, 1707–1712.PubMedCrossRefGoogle Scholar
  59. 59.
    Kadish, A., Dyer, A., Daubert, J. P., Quigg, R., Estes, N. A. M., Anderson, K. P., et al. (2004). Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. New England Journal of Medicine, 351, 2151–2158.CrossRefGoogle Scholar
  60. 60.
    Theuns, D. A. M. J., Klootwijk, P. J., Goedhart, D. M., & Jordaens, L. J. L. M. (2004). Prevention of inappropriate therapy in implantable cardioverter-defibrillators: Results of a prospective, randomized study of tachyarrhythmia detection algorithms. Journal of the American College of Cardiology, 44, 2362–2367.PubMedCrossRefGoogle Scholar
  61. 61.
    Disenhofer, I., Kolb, C., Ndrepepa, G., Schreieck, J., Karch, M., Schmieder, S., et al. (2001). Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study. Journal of Cardiovascular Electrophysiology, 12, 134–142.CrossRefGoogle Scholar
  62. 62.
    Kuhlkamp, V., Dornberger, V., Mewis, C., Suchalla, R., Bosch, R. F., Seipel, L. (1999). Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. Journal of Cardiovascular Electrophysiology, 10, 905–915.PubMedGoogle Scholar
  63. 63.
    Sweeney, M. O., Wathen, M. S., Volosin, K., Abdalla, I., DeGroot, P. J., Otterness, M. F., et al. (2005). Appropriate and inappropriate ventricular therapies, quality of life and mortality among primary and secondary prevention ICD patients: Results from PainFREE Rx II. Circulation, 111, 2898–2905.PubMedCrossRefGoogle Scholar
  64. 64.
    Namerow, P. B., Firth, B. R., Heywood, G. M., Windle, J. R., Parides, M. K., for the CABG Patch Trial Investigators and Coordinators (1999). Quality of Life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: Findings from the CABG Patch Trial. Pacing and Clinical Electrophysiology, 22, 1305–1313.PubMedCrossRefGoogle Scholar
  65. 65.
    Schron, E. B., Exner, D. V., Yao, Q., Jenkins, L. S., Steinberg, J. S., Cook, J. R., et al. (2002). Quality of life in the antiarrhythmics versus implantable defibrillators trial. Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation, 105, 589–594.PubMedCrossRefGoogle Scholar
  66. 66.
    Irvine, J., Dorian, P., Baker, B., O’Brien, B. J., Roberts, R., Gent, M. et al. (2002). Quality of life in the Canadian Implantable Defibrillator Study (CIDS). American Heart Journal, 144, 282–289.PubMedGoogle Scholar
  67. 67.
    Cleland, J. G. F., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D.,Kappenberger, L., et al. (2006). Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal, 27, 1928–1932.PubMedCrossRefGoogle Scholar
  68. 68.
    Mark, D. B., Nelson, C. L., Anstrom, K. J., Al-Khatib, S. M., Tsiatis, A. A., Cowper, P. A., et al. (2006). Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 114, 135–142.PubMedCrossRefGoogle Scholar
  69. 69.
    Zwanziger, J., Hall, W. J., Dick, A. W., Zhao, H., Mushlin, A. I., Hahn, R. M., et al. (2006). The cost effectiveness of implantable cardioverter-defibrillators: Results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. Journal of the American College of Cardiology, 47, 2310–2318.PubMedCrossRefGoogle Scholar
  70. 70.
    Hauser, R. G. (2005). The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. Journal of the American College of Cardiology, 45, 2022–2025.PubMedCrossRefGoogle Scholar
  71. 71.
    Calvert, M. J., Freemantle, N., Yao, G., Cleland, J. G. F., Billingham, L., Daubert, J. C., et al. (2005). Cost-effectiveness of cardiac resynchronization therapy: Results from the CARE-HF Trial. European Heart Journal, 26, 2681–2688.PubMedCrossRefGoogle Scholar
  72. 72.
    Feldman, A. M., de Lissovoy, G., Bristow, M. R., Saxon, L. A., De Marco, T., Kass, D. A., et al. (2005). Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Journal of the American College of Cardiology, 46, 2311–2321.PubMedCrossRefGoogle Scholar
  73. 73.
    Moss, A. J. (2000). Implantable cardioverter defibrillator therapy: The sickest patients benefit the most. Circulation, 101, 1638–1640.PubMedGoogle Scholar
  74. 74.
    Uretsky, B., & Sheahan, G. (1997). Primary prevention of sudden cardiac death in heart failure: Will the result be shocking? Journal of the American College of Cardiology, 30, 1589–1597.PubMedCrossRefGoogle Scholar
  75. 75.
    Luu, M., Stevenson, W. G., Saxon, L. A., & Stevenson, L. W. (1989). Diverse mechanisms of unexpected cardiac arrest in heart failure. Circulation, 80, 1675–1680.PubMedGoogle Scholar
  76. 76.
    Mitchell, L. B., Pineda, E. A., Titus, J. L., Bartosch, P. M., & Benditt, D. G. (2002). Sudden death in patients with implantable cardioverter defibrillators: Importance of post-shock electromechanical dissociation. Journal of the American College of Cardiology, 39, 1323–1328.PubMedCrossRefGoogle Scholar
  77. 77.
    Moss, A. J., Greenberg, H., Case, R. B., Zareba, W., Hall, W. J., Brown, M. W., et al. (2004). Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation, 110, 3760–3765.PubMedCrossRefGoogle Scholar
  78. 78.
    Goldenberg, I., Moss, A. J., Hall, W. J., McNitt, S., Zareba, W., Andrews, M. L., et al. (2006). Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation, 113, 2810–2817.PubMedCrossRefGoogle Scholar
  79. 79.
    Grimm, W., Christ, M., Bach, J., Muller, H. H., Maisch, B. (2003). Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: Results of the Marburg Cardiomyopathy Study. Circulation, 108, 2883–2891.PubMedCrossRefGoogle Scholar
  80. 80.
    Bentkover, J. D., Stewart, E. J., Ignaszewski, A., Lepage, S., Liu, P., & Cooper, J. (2003). New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada. International Journal of Cardiology, 88, 33–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Cardiac Arrhythmia ServiceBrigham and Women’s HospitalBostonUSA

Personalised recommendations